Company Filing History:

1 out of 377

Aventis Pharma S.a.

patents

1 out of 1

Aventis Pharma S.a. Deutschland Gmbh Genentech, Inc.

patent

5 out of 832,718

Other

patents

Years Active: 2001-2004

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6762190 - Thienylalanine derivatives as inhibitors of cell adhesion (2004-07-13),

2. 6743800 - Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them (2004-06-01),

3. 6660728 - Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists (2003-12-09),

4. 6566366 - Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists (2003-05-20),

5. 6492356 - Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists (2002-12-10),

6. 6340679 - Guanidine derivatives as inhibitors of cell adhesion (2002-01-22),

7. 6277845 - Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates (2001-08-21),

Title: The Innovations of Karl-Heinz Scheunemann

Introduction

Karl-Heinz Scheunemann is a notable inventor based in Liederbach, Germany. He has made significant contributions to the field of pharmacology, holding a total of 7 patents. His work primarily focuses on developing compounds that have valuable pharmacological properties.

Latest Patents

One of his latest patents involves thienylalanine derivatives as inhibitors of cell adhesion. This invention relates to compounds of formula (I), which are pharmacologically active and serve as vitronectin receptor antagonists. These compounds are suitable for the therapy and prophylaxis of various illnesses that stem from the interaction between vitronectin receptors and their ligands. For instance, they can be utilized to inhibit bone resorption by osteoclasts, thereby treating and preventing osteoporosis. Additionally, they can help in inhibiting undesired angiogenesis or the proliferation of vascular smooth muscle cells. The patent also covers processes for preparing these compounds and their use as active ingredients in pharmaceuticals.

Career Highlights

Throughout his career, Karl-Heinz Scheunemann has worked with prominent companies, including Aventis Pharma S.A. His innovative work has led to advancements in therapeutic applications, particularly in the realm of cell adhesion and receptor interactions.

Collaborations

He has collaborated with notable individuals in the field, including Jean-Francois Gourvest and Thomas Gadek. These collaborations have contributed to the development of his patented inventions and have enhanced the impact of his work in pharmacology.

Conclusion

Karl-Heinz Scheunemann's contributions to the field of pharmacology through his innovative patents demonstrate his commitment to advancing medical science. His work continues to influence therapeutic strategies for various diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.